• Publications
  • Sharing surveillance data: the value of colla...
Published on 20 Nov 2020

Sharing surveillance data: the value of collaboration in curbing the next pandemic

Routine drug resistance surveillance is essential for monitoring and controlling the spread of diseases and has proven to be a critical element of addressing the COVID-19 pandemic. Routine surveillance is also a crucial element in controlling the rise of antimicrobial resistance. 

In this viewpoint, authors Francesca Chiara (Senior Advisor, Drug Resistant Infections Programme, Wellcome); Moska Hellamand (Researcher, Access to Medicine Foundation); and Margo Warren (Government Engagement and Policy Manager, Access to Medicine Foundation) make the case for pharmaceutical companies to share surveillance data sets publicly, including through the AMR Register. 

Explore further

Get in touch

Back to top |